Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: LLCF who wrote (6295)	1/15/1999 11:57:00 PM
From: scaram(o)uche	Respond to of 9719

biz.yahoo.com Management hates it. ;-) price:book = 0.7 "Also during the fiscal 1999 first quarter, the Company recorded compensation expense of $1.8 million in connection with a cash-out of stock options for Cohesion Corporation, a majority-owned subsidiary of Cohesion Technologies. The Company expects to record up to an additional $4.0 million in cash compensation expense over the next three fiscal years. Gain on sale of investments for the fiscal 1999 first quarter was $9.6 million primarily from the sale of 125,000 shares of Boston Scientific (NYSE: BSX - news) common stock. Currently, the Company holds approximately 900,000 shares of BSX, 88% of which are hedged with ''equity collars'' from $63 - $98 per share. The Company expects to continue selling shares of BSX stock on a quarterly basis to fund its operations; however, the number of BSX shares sold on a quarterly basis is expected to fluctuate significantly from quarter to quarter due in part to the timing of the equity collars and the price at which BSX stock is trading, among other factors. During the fiscal 1999 first quarter, the Company repurchased 50,000 shares of its common stock in the open market. As of September 30,1998, Cohesion Technologies had cash and marketable securities of approximately $75 million." Interesting. How much money is there in diffuse bleeding?